bloodjourГематология и трансфузиологияRussian journal of hematology and transfusiology0234-57302411-3042ООО Издательский дом «Практика»10.35754/0234-5730-2024-69-3-320-329bloodjour-578Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESСтатистические данные о миелодиспластическом синдроме в Российской ФедерацииStatistical Data on Myelodysplastic Syndrome in the Russian Federationhttps://orcid.org/0000-0003-0261-5941КохноА. В.KokhnoA. V.

Кохно Алина Владимировна, кандидат медицинских наук, заведующая отделом диагностики и лечения гематологических заболеваний

125167, г. Москва

Alina V. Kokhno, Cand. Sci. (Med.), Head of the Department of Diagnostics and Treatment of Hematological Diseases

125167, Moscow

kohno@blood.ruhttps://orcid.org/0000-0002-0889-0445ЛазареваО. В.LazarevaO. V.

Лазарева Ольга Вениаминовна, кандидат медицинских наук, руководитель управления регионального и межведомственного сотрудничества по профилю «гематология» 

125167, г. Москва

Olga V. Lazareva, Cand. Sci. (Med.), Head of the Department of Regional and Interdepartmental Cooperation in the Field of Hematology

125167, Moscow

lazareva.o@blood.ruhttps://orcid.org/0000-0001-7193-4503МалолеткинаЕ. С.MaloletkinaE. S.

Малолеткина Елизавета Сергеевна, начальник организационно-методического отдела по работе с субъектами Российской Федерации, методист 

125167, г. Москва

Elizaveta  S.  Maloletkina,  Head of the Organizational and Methodological Department for work with the Constituent Entities of the Russian Federation, methodologist

125167, Moscow

maloletkina.e@blood.ruhttps://orcid.org/0000-0001-6177-3566ПаровичниковаЕ. Н.ParovichnikovaE. N.

Паровичникова Елена Николаевна, доктор медицинских наук, генеральный директор 

125167, г. Москва

Elena  N.  Parovichnikova, Dr. Sci. (Medicine), CEO 

125167, Moscow

parovichnikova.e@blood.ruФГБУ «Национальный медицинский исследовательский центр гематологии» Министерства здравоохранения Российской ФедерацииРоссияNational Medical Research Center for HematologyRussian Federation202425112024693320329Copyright © Кохно А.В., Лазарева О.В., Малолеткина Е.С., Паровичникова Е.Н., 20242024Кохно А.В., Лазарева О.В., Малолеткина Е.С., Паровичникова Е.Н.Kokhno A.V., Lazareva O.V., Maloletkina E.S., Parovichnikova E.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.htjournal.ru/jour/article/view/578Введение

Введение. Миелодиспластический синдром (МДС) — нозология, требующая обследования с использованием цитогенетического, молекулярно-генетического и иммунофенотипического исследований костного мозга и/или крови, а также выполнения трепанобиопсии костного мозга с патоморфологическим и иммуногистохимическим исследованиями. В Российской Федерации (РФ) до недавнего времени официальный статистический учет МДС не осуществляли.

Цель

Цель: представить данные о заболеваемости и распространенности МДС в РФ на основании данных официальных статистических форм.

Материалы и методы

Материалы и методы. Представлена информация форм федерального статистического наблюдения № 7 «Сведения о злокачественных новообразованиях» (ФФСН) за 2022 и 2023 гг. о заболеваемости и распространенности МДС, актуализированных по инициативе ФГБУ «НМИЦ гематологии» Минздрава России; в таблицу 2100 впервые введены дополнительные строки (35–37) со сведениями о движении больных, в том числе с МДС (код D46 по МКБ-10).

Результаты

Результаты. Согласно данным ФФСН № 7, в 2022 и 2023 гг. было зарегистрировано 2827 и 3411 случаев МДС соответственно. Расчетная первичная заболеваемость по РФ составила 0,58 и 0,50 на 100 тыс. взрослого населения в 2022 и 2023 гг. соответственно, а распространенность — 2,4 на 100 тыс. взрослого населения. Расчетная заболеваемость МДС по федеральным округам в 2022 г. составила от 0,13 до 1,05 с вариациями от 0,03 до 2,57 на 100 тыс. взрослого населения в зависимости от региона проживания. Под диспансерным наблюдением на конец 2023 г. зарегистрировано 3001 (88 %) больных МДС, из них под наблюдением в течение 5 лет и более — 860 (28,7 %) человек.

Заключение

Заключение. Полученные данные о заболеваемости и распространенности МДС показали значимость проведенной работы как для последующего совершенствования системы регистрации и учета больных заболеваниями системы крови в целом и МДС в частности в РФ, так и позволят использовать их при планировании в здравоохранении РФ.

Introduction

Introduction. Myelodysplastic syndrome (MDS) is a nosology that requires examination using cytogenetic, molecular-genetic and immunophenotypic analysis of bone marrow and/or blood, as well as mandatory bone marrow trepan biopsy with pathomorphological and immunohistochemically studies. Until recently, there was no official statistical data on MDS in Russia.

Aim

Aim: to present data on the incidence and prevalence of MDS in Russia based on official statistical forms.

Materials and methods

Materials and methods. Information from statistical form №7 «Information on malignant neoplasms» (SF No. 7) for 2022 and 2023 on the incidence and prevalence of MDS, updated at the initiative of the National Medical Research Center for Hematology, is presented. For the first time, additional lines (35–37) with information on the movement of patients, including MDS (code D46 according to ICD-10), have been introduced into table 2100.

Results

Results. According to SF No. 7, in 2022 and 2023, 2,827 and 3,411 cases of MDS were registered, respectively. The estimated primary incidence in the Russian Federation was 0.58 and 0.50 per 100 thousand of the adult population in 2022 and 2023, respectively, and the prevalence was 2.4 per 100 thousand of the adult population. The estimated incidence of MDS by federal districts in 2022 ranged from 0.13 to 1.05 with variations from 0.03 to 2.57 per 100 thousand of the adult population, depending on the region of residence. At the end of 2023, 3001 (88 %) patients with MDS were registered under dispensary observation, of which 860 (28.7 %) were under observation for 5 years or more.

Conclusion

Conclusion. The obtained statistical data on the incidence and prevalence of MDS showed the high significance of the work carried out both for the subsequent improvement of the system of registration of patients with diseases of the blood system in general, and MDS, particularly the Russian Federation, and will make it possible to use this data in the planning of healthcare in the Russia.

гематологиягематологическая службамиелодиспластический синдромстатистический учетраспространенностьзаболеваемостьраковый регистрhematologyhematology servicemyelodysplastic syndromestatisticsprevalenceincidencecancer registryReferencesКохно А.В., Паровичникова Е.Н., Михайлова Е.А. Алгоритмы обследования и протоколы лечения больных с различными формами миелодиспластических. В книге «Алгоритмы диагностики и протоколы лечения заболеваний системы крови» Под ред. Е.Н. Паровичниковой. Т. 1. М.: Практика, 2024: 551–64.Kokhno A.V., Parovichnikova E.N., Mikhailova E.A. Algorithms for examination and treatment protocols for patients with various forms of myelodysplastic. Diagnostic algorithms and treatment protocols for diseases of the blood system: in two volumes. Ed E.N. Parovichnikova. Moscow: Praktika, 2024; 1: 551–64 (In Russian).Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classifi cation of the myelodysplastic syndromes. Br J Haematol. 1982; 51: 189–99.Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classifi cation of the myelodysplastic syndromes. Br J Haematol. 1982; 51: 189–99.Fritz A., Percy C., Jack A. (Eds.). International Classifi cation of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization. 2013Fritz A., Percy C., Jack A. (Eds.). International Classifi cation of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization.Jaffe E.S., Harris N., Stein H., Vardiman J.W. (Eds.): World Health Organization classifi cation of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. 3rd ed. Lyon: IARC; 2001.Jaffe E.S., Harris N., Stein H., Vardiman J.W. (Eds.): World Health Organization classifi cation of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. 3rd ed. Lyon: IARC; 2001.Swerdlow S.H., Campo E., Harris N.L., et al. (Eds.): World Health Organization classifi cation of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC 2008.Swerdlow S.H., Campo E., Harris N.L., et al. (Eds.): World Health Organization classifi cation of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC 2008.Swerdlow S.H., Campo E., Harris N.L., et al. (Eds.): World Health Organization classifi cation of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. Lyon: IARC; 2017.Swerdlow S.H., Campo E., Harris N.L., et al. (Eds.): World Health Organization classifi cation of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. Lyon: IARC; 2017.WHO Classifi cation of Tumours Online. Haematolymphoid tumours. Beta version ahead of print. 5th ed. France, Lyon: International Agency for Research on Cancer; 2022. https://tumourclassification.iarc.who.int/chapters/63WHO Classifi cation of Tumours Online. Haematolymphoid tumours. Beta version ahead of print. 5th ed. France, Lyon: International Agency for Research on Cancer; 2022. https://tumourclassification.iarc.who.int/chapters/63Асауленко З.П., Спиридонов И.Н., Барам Д.В., Криволапов Ю.А. Классификация ВОЗ опухолей гемопоэтической и лимфоидной тканей 2022 г. (5-е изд.): миелоидные и гистиоцитарные новообразования. Архив патологии. 2023; 85(5): 36–44. DOI: 10.17116/patol20238505136.Asaulenko Z.P., Spiridonov I.N., Baram D.V., Krivolapov Yu.A. WHO Classifi - cation of Tumors of Hematopoietic and Lymphoid Tissues, 2022 (5th edition): Myeloid and Histiocytic Tumors. Arkhive Pathologii. 2023; 85(5): 36–44 (In Russian). DOI: 10.17116/patol20238505136.Ma X. Epidemiology of myelodysplastic syndromes. Am J Med. 2012; 125 (7 Suppl): S2–5.Ma X. Epidemiology of myelodysplastic syndromes. Am J Med. 2012; 125(7 Suppl): S2–5.Rollison D.E., Howlader N., Smith M.T., et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood. 2008; 112(1): 45–52.Rollison D.E., Howlader N., Smith M.T., et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood. 2008; 112(1): 45–52.Greenberg P.L., Stone R.M., Al-Kali A., et al. NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022: Featured Updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2022; 20(2): 106–17. DOI: 10.6004/jnccn.2022.0009.Greenberg P.L., Stone R.M., Al-Kali A., et al. NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022: Featured Updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2022; 20(2): 106–17. DOI: 10.6004/jnccn.2022.0009.Bonadies N., Feller A., Rovo A., et al. Trends of classifi cation, incidence, mortality, and survival of MDS patients in Switzerland between 2001 and 2012. Cancer Epidemiol. 2017; 46: 85–92.Bonadies N., Feller A., Rovo A., et al. Trends of classifi cation, incidence, mortality, and survival of MDS patients in Switzerland between 2001 and 2012. Cancer Epidemiol. 2017; 46: 85–92.Dinmohamed A.G., Visser O., Van Norden Y., et al. Trends in incidence, initial treatment and survival of myelodysplastic syndromes: A population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010. Eur J Cancer. 2014; 50(5): 1004–12.Dinmohamed A.G., Visser O., Van Norden Y., et al. Trends in incidence, initial treatment and survival of myelodysplastic syndromes: A population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010. Eur J Cancer. 2014; 50(5): 1004–12.Kontro S., Raitanen J., Porkka K., et al. Incidence of myelodysplastic syndromes in Finland 1997–2016. Leuk Res. 2022; 116: 106839. DOI: 10.1016/j.leukres.2022.106839.Kontro S., Raitanen J., Porkka K., et al. Incidence of myelodysplastic syndromes in Finland 1997–2016. Leuk Res. 2022; 116: 106839. DOI: 10.1016/j.leukres.2022.106839.Neukirchen J., Schoonen W. M., Strupp C., et al. Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry. Leuk Res. 2011; 35(12): 1591–6. DOI: 10.1016/j.leukres.2011.06.001.Neukirchen J., Schoonen W. M., Strupp C., et al. Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry. Leuk Res. 2011; 35(12): 1591–6. DOI: 10.1016/j.leukres.2011.06.001.Avgerinou C., Alamanos Y., Zikos P., et al. The incidence of myelodysplastic syndromes in Western Greece is increasing. Ann Hematol. 2013; 92(7): 877–87. DOI: 10.1007/s00277-013-1712-6.Avgerinou C., Alamanos Y., Zikos P., et al. The incidence of myelodysplastic syndromes in Western Greece is increasing. Ann Hematol. 2013; 92(7): 877–87. DOI: 10.1007/s00277-013-1712-6.Slack J., Nguyen L., Naugler C., et al. Incidence of Myelodysplastic Syndromes in a Major Canadian Metropolitan Area. J Appl Lab Med. 2018; 3(3): 378–83. DOI: 10.1373/jalm.2018.026500.Slack J., Nguyen L., Naugler C., et al. Incidence of Myelodysplastic Syndromes in a Major Canadian Metropolitan Area. J Appl Lab Med. 2018; 3(3): 378–83. DOI: 10.1373/jalm.2018.026500.Rodger E., Morison I. Myelodysplastic syndrome in New Zealand and Australia. Int Med J. 2012; 42(11): 1235–42. DOI: 10.1111/j.1445-5994.2011.02619.x.Rodger E., Morison I. Myelodysplastic syndrome in New Zealand and Australia. Int Med J. 2012; 42(11): 1235–42. DOI: 10.1111/j.1445-5994.2011.02619.x.McQuilten Z.K., Polizzotto M.N., Wood E.M., et al. Myelodysplastic syndrome incidence, transfusion dependence, health care use, and complications: an Australian population based study 1998 to 2008. Transfusion. 2013; 53(8): 1714–21. DOI: 10.1111/trf.12054.McQuilten Z.K., Polizzotto M.N., Wood E.M., et al. Myelodysplastic syndrome incidence, transfusion dependence, health care use, and complications: an Australian population based study 1998 to 2008. Transfusion. 2013; 53(8): 1714–21. DOI: 10.1111/trf.12054.Chihara D., Ito H., Katanoda K., et al. Incidence of myelodysplastic syndrome in Japan. J Epidemiol. 2014; 24(6): 469–73. DOI: 10.2188/jea.je20140042.Chihara D., Ito H., Katanoda K., et al. Incidence of myelodysplastic syndrome in Japan. J Epidemiol. 2014; 24(6): 469–73. DOI: 10.2188/jea.je20140042.Baptista R.L.R., Dos Santos A.C.E., Gutiyama L.M., et al. Familial Myelodysplastic / Acute Leukemia Syndromes-Myeloid Neoplasms with Germline Predisposition. Front Oncol. 2017; 7: 206. DOI: 10.3389/fonc.2017.00206.Baptista R.L.R., Dos Santos A.C.E., Gutiyama L.M., et al. Familial Myelodysplastic / Acute Leukemia Syndromes-Myeloid Neoplasms with Germline Predisposition. Front Oncol. 2017; 7: 206. DOI: 10.3389/fonc.2017.00206.Wang W., Wang H., Wang X.-Q., et al. First report of incidence of adult myelodysplastic syndrome in China. Ann Hematol. 2024; 91(8): 1321–2. DOI: 10.1007/s00277-011-1389-7.Wang W., Wang H., Wang X.-Q., et al. First report of incidence of adult myelodysplastic syndrome in China. Ann Hematol. 2024; 91(8): 1321–2. DOI: 10.1007/s00277-011-1389-7.Paydas S. Young age MDS: differences between Western and Eastern countries. Leuk Res. 2006; 30(3): 362–464. DOI: 10.1016/j.leukres.2005.07.005.Paydas S. Young age MDS: differences between Western and Eastern countries. Leuk Res. 2006; 30(3): 362–464. DOI: 10.1016/j.leukres.2005.07.005.Galaverna F., Ruggeri A., Locatelli F. Myelodysplastic syndromes in children. Curr Opin Oncol. 2018; 30(6): 402–8. DOI: 10.1097/CCO.0000000000000488.Galaverna F., Ruggeri A., Locatelli F. Myelodysplastic syndromes in children. Curr Opin Oncol. 2018; 30(6): 402–8. DOI: 10.1097/CCO.0000000000000488.Hasle H. Myelodysplastic and myeloproliferative disorders of childhood. Hematology 2014, the American Society of Hematology Education Program Book. 2016; 1: 598–604. DOI: 10.1182/asheducation-2016.1.598.Hasle H. Myelodysplastic and myeloproliferative disorders of childhood. Hematology 2014, the American Society of Hematology Education Program Book. 2016; 1: 598–604. DOI: 10.1182/asheducation-2016.1.598.Jiang Y., Eveillard J. R., Couturier M. A., et al. Asian population is more prone to develop high-risk myelodysplastic syndrome, concordantly with their propensity to exhibit high-risk cytogenetic aberrations. Cancers. 2021; 13(3): 1–23. DOI: 10.3390/cancers13030481.Jiang Y., Eveillard J. R., Couturier M. A., et al. Asian population is more prone to develop high-risk myelodysplastic syndrome, concordantly with their propensity to exhibit high-risk cytogenetic aberrations. Cancers. 2021; 13(3): 1–23. DOI: 10.3390/cancers13030481.Семочкин С.В., Дудина Г.А., Толстых Т.Н. Эпидемиология миелодиспластических синдромов в г. Москве по данным регионального регистра. Медицинский вестник Башкортостана. 2017; 12(2): 153–6.Semochkin S.V., Dudina G.A., Tolstykh T.N. Epidemiology of myelodysplastic syndromes in Moscow according to regional registry data. Meditsinskiy Vestnik Bashkortostanf. 2017; 12(2): 153–6 (In Russian).Паспорт национального проекта «Здравоохранение» (утв. президиумом Совета при Президенте Российской Федерации по стратегическому развитию и национальным проектам, протокол от 24 декабря 2018 г. № 16). http://government.ru/info/35561/Passport of the national project “Healthcare” (approved by the Presidium of the Council under the President of the Russian Federation for Strategic Development and National Projects, protocol of December 24, 2018, No. 16). URL: http://government.ru/info/35561/ [cited 20 September 2024] (In Russian).Каприн А.Д., Чиссов В.И., Старинский В.В. и др. Информационно-аналитическая система учета онкологических больных РФ. Онкология. Журнал им. П.А. Герцена. 2015; 4(5): 40–3. DOI: 10.17116/onkolog20154540-43.Kaprin A.D., Chissov V.I., Starinsky V.V., Gretsova O.P., Petrova G.V., Prostov Yu.I. Information and analytical system for recording cancer patients in the Russian Federation. Oncologiya. Zournal imeni Gertsena. 2015; 4(5): 40–3 (In Russian). DOI: 10.17116/onkolog20154540-43.Приказ Росстата от 27.12.2022 № 985 «Об утверждении форм федерального статистического наблюдения с указаниями по их заполнению для организации Министерством здравоохранения Российской Федерации федерального статистического наблюдения в сфере охраны здоровья». https://www.consultant.ru/document/cons_doc_LAW_436893/Order of Rosstat dated 27.12.2022 No. 985 “On approval of federal statistical monitoring forms with instructions for fi lling them out for the organization of federal statistical monitoring in the fi eld of health protection by the Ministry of Health of the Russian Federation» URL: https://www.consultant.ru/document/cons_doc_LAW_436893/ [updated 2024; cited 20 September 2024] (In Russian).Миелодиспластический синдром. Рубрикатор клинических рекомендаций. 2024 https://cr.minzdrav.gov.ru/recomend/141Myelodysplastic syndrome. Rubricator of clinical recommendations, 2024 [updated 2024; cited 20 September 2024]. Available at: https://cr.minzdrav.gov.ru/recomend/141 (In Russian).McQuilten Z.K., Wood E.M., Polizzotto M.N., et al. Underestimation of myelodysplastic syndrome incidence by cancer registries: Results from a populationbased data linkage study. Cancer. 2014; 120(11): 1686–94. DOI: 10.1002/cncr.28641.McQuilten Z.K., Wood E.M., Polizzotto M.N., et al. Underestimation of myelodysplastic syndrome incidence by cancer registries: Results from a populationbased data linkage study. Cancer. 2014; 120(11): 1686–94. DOI: 10.1002/cncr.28641.Лазарева О.В., Малолеткина Е.С., Туаева А.А. и др. Технология оценки качества оказания медицинской помощи по профилю «гематология» в субъектах Российской Федерации при проведении выездных мероприятий. Вопросы онкологии. 2022; 68(S3): 60–1.Lazareva O.V., Maloletkina E.S., Tuaeva A.A., et al. Technology for assessing the quality of medical care in the fi eld of «hematology» in the constituent entities of the Russian Federation during outreach activities. Voprosy onkologii. 2022; 68(S3): 60–1 (In Russian).Двирнык В.Н., Кохно А.В., Чулкова А.А. и др. Цитологическая и цитохимическая диагностика сидеробластных анемий. Гематология и трансфузиология. 2024; 69(1): 80–8. DOI: 10.35754/0234-5730-2024-69-1-80-88.Dvirnyk V.N., Kokhno A.V., Chulkova A.A., et al. Cytological and cytochemical diagnostics of sideroblastic anemias. Gematologiya I Trnasfusiologiya. 2024; 69(1): 80–8 (In Russian). DOI: 10.35754/0234-5730-2024-69-1-80-88.Цаур Г.А., Ольшанская Ю.В., Обухова Т.Н. и др. Цитогенетическая и молекулярно-генетическая диагностика онкогематологических заболеваний: позиция Организации молекулярных генетиков в онкологии и онкогематологии. Гематология и трансфузиология. 2023; 68(1): 129–43. DOI: 10.35754/0234-5730-2023-68-1-129-143.Tsaur G.A., Olshanskaya Yu.V., Obukhova T.N., et al. Cytogenetic and molecular genetic diagnostics of oncohematological diseases: position of the Organization of Molecular Geneticists in Oncology and Oncohematology. Gematologiya I Trnasfusiologiya. 2023; 68(1): 129–43 (In Russian). DOI: 10.35754/0234-5730-2023-68-1-129-143.Диагностика заболеваний системы крови. Практическое руководство. Под ред. Е.Н. Паровичниковой и И.В. Гальцевой. М.: Практика, 2024: 547–59.Diagnostics of diseases of the blood system. Practical guide. Eds E.N. Parovichnikova, I.V. Galtseva. Moscow: Praktika, 2024: 547–59 (In Russian).Малолеткина Е.С., Лазарева О.В., Паровичникова Е.Н., Кохно А.В. Организационные вопросы выполнения трепанобиопсии костного мозга врачамигематологами. Гематология и трансфузиология. 2024; 69(Прил. 2): 269–70.Maloletkina E.S., Lazareva O.V., Parovichnikova E.N., Kokhno A.V. Organizational issues of performing bone marrow trepanobiopsy by hematologists. Gematologiya I Trnasfusiologiya. 2024; 69(Suppl. 2): 269–70 (In Russian).Cogle C.R. Incidence and Burden of the Myelodysplastic Syndromes. Curr Hematol Malig Rep. 2015; 10(3): 272–81. DOI: 10.1007/s11899-015-0269-y.Cogle C.R. Incidence and Burden of the Myelodysplastic Syndromes. Curr Hematol Malig Rep. 2015; 10(3): 272–81. DOI: 10.1007/s11899-015-0269-y.Craig B.M., Rollison D.E., List A.F., Cogle C.R. Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromes. Leuk Res. 2011; 35(11): 1453–6. DOI: 10.1016/j.leukres.2011.07.028.Craig B.M., Rollison D.E., List A.F., Cogle C.R. Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromes. Leuk Res. 2011; 35(11): 1453–6. DOI: 10.1016/j.leukres.2011.07.028.Goldberg S.L., Chen E., Sasane M., et al. Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need. Transfusion. 2012; 52: 2131–8. DOI: 10.1111/j.1537-2995.2012.03626.xGoldberg S.L., Chen E., Sasane M., et al. Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need. Transfusion. 2012; 52: 2131–8. DOI: 10.1111/j.1537-2995.2012.03626.x.United Nations, Department of Economic and Social Affairs, Population Division (2024). World Population Prospects 2024: Summary of Results. UN DESA/ POP/2024. URL: https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/undesa_pd_2024_wpp_2024_advance_unedited_0.pdf (дата обращения: 20.09.2024).United Nations, Department of Economic and Social Affairs, Population Division (2024). World Population Prospects 2024: Summary of Results. UN DESA/ POP/2024. URL: https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/undesa_pd_2024_wpp_2024_advance_unedited_0.pdf [cited 20 September 2024].

The authors declare that there are no conflicts of interest present.